For recurrent yeast infections, suppression works — but mostly while you keep taking it
Weekly fluconazole kept most women free of thrush during treatment, yet by 12 months, six months after stopping, the advantage had narrowed sharply. A newer drug shows more durable suppression.
Recurrent vulvovaginal candidiasis — repeated bouts of what most people call a yeast infection — has a treatment that clearly works, with an important limit: it suppresses recurrences while a woman keeps taking it, and the protection fades once she stops [s1]. That pattern, established in a landmark trial and reinforced by a newer drug, is the single most useful thing to understand about the condition [s1] [s2].
The trial that set the approach
In a study published in the New England Journal of Medicine, researchers first brought 387 women with recurrent yeast infections into remission using open-label fluconazole, given as three 150-mg doses 72 hours apart [s1]. They then randomly assigned the women to weekly fluconazole (150 mg) or placebo for six months, followed by six months of observation with no treatment [s1].
While the drug was being taken, it worked well. The proportion of women who remained free of symptomatic disease at six months was 90.8% on fluconazole, against 35.9% on placebo [s1]. But the follow-up months tell the rest of the story. At nine months the figures were 73.2% versus 27.8%, and at 12 months — six months after treatment stopped — they were 42.9% versus 21.9% [s1]. The median time to clinical recurrence was 10.2 months on fluconazole versus 4.0 months on placebo (all comparisons P<0.001) [s1].
The authors' own conclusion is the honest one: long-term weekly fluconazole reduces the rate of recurrence, but "a long-term cure remains difficult to achieve" [s1]. Suppression is not the same as eradication. Reassuringly, they found no evidence of fluconazole resistance developing in Candida albicans, and no superinfection with the harder-to-treat C. glabrata [s1].
A newer drug, more durable suppression
Since that trial, a longer-acting antifungal, oteseconazole, has been approved specifically for recurrent vulvovaginal candidiasis [s2]. In two identically designed phase III studies, oteseconazole was superior to placebo through 48 weeks for preventing recurrence, with recurrence rates of 6.7% versus 42.8% in one and 3.9% versus 39.4% in the other (both P<0.001) [s2]. In the one phase III trial that compared it against an active drug, oteseconazole was non-inferior to fluconazole for treating the acute infection and superior to placebo for preventing recurrence through 50 weeks (5.1% versus 42.2%, P<0.001) [s2]. The review notes it is also effective against fluconazole-resistant Candida [s2].
That is a genuine step up in the durability of suppression over a longer window than the older weekly regimen was tested across. It does not rewrite the underlying reality — recurrent yeast infection is a condition managed rather than cured — but it widens the options for doing that managing.
What the numbers do and do not tell a reader
Both of these are efficacy studies in women who already had a diagnosis of recurrent disease, defined and confirmed clinically. They say nothing about whether a given episode of vaginal itching or discharge is in fact a yeast infection — a question that trips up self-treatment, because the same symptoms are caused by bacterial vaginosis and other conditions that antifungals do not touch. Nor do these trials speak to the single, occasional yeast infection, which is a different clinical situation from the recurrent form these drugs were built for.
There is also a dosing and safety dimension these summaries deliberately do not resolve here: antifungal drugs carry their own cautions, interactions and contraindications, and oteseconazole in particular is not for everyone. Those are matters for a prescriber, not a web page.
The liftable version: for women with genuinely recurrent yeast infections, maintenance antifungal therapy has strong trial evidence for keeping symptoms away — most reliably while it is being taken, with a newer agent offering more durable protection over roughly a year. The expectation to correct is that any of these produces a permanent cure; the trials themselves say otherwise.
This article is informational and is not medical advice. Diagnosis of recurrent vulvovaginal candidiasis, and any antifungal treatment, should be handled by a qualified clinician.
Sources
- Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis — New England Journal of Medicine , August 25, 2004
- Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review — Annals of Pharmacotherapy , August 31, 2023
Bacterial vaginosis keeps coming back — and treating the male partner cut recurrence
Most women have a recurrence within a year of standard treatment. A 2025 trial stopped early once treating a woman alone proved inferior to treating her and her male partner together.
For recurrent UTIs, a non-antibiotic pill matched daily antibiotics in a trial
In the 240-woman ALTAR trial, methenamine hippurate was non-inferior to standard low-dose antibiotic prophylaxis over a year. Most other non-antibiotic prevention strategies still rest on weak evidence.
The morning-after pill works less well the later you take it — and at higher weight
Trials put the pregnancy rate after emergency contraceptive pills at roughly 1-3%. But the risk rose more than threefold in obese women, and the levonorgestrel pill fared worst of all.
Your mammogram now reports breast density. Here is what that actually means.
Dense tissue raises breast-cancer risk and hides cancers on a mammogram. US facilities must now tell patients — but the evidence on what to do next is a real trade-off: more cancers found, more false alarms.